{"brief_title": "Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder", "brief_summary": "To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.", "condition": ["Major Depressive Disorder"], "intervention_type": ["Drug"], "intervention_name": ["DVS-233 SR"], "criteria": "Inclusion Criteria: - Men and women 18 to 75 years of age, inclusive. - Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article - Subjects must have a primary diagnosis of major depressive disorder Exclusion Criteria: - Treatment with DVS-233 SR at any time in the past - Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1 - Known hypersensitivity to venlafaxine (IR or ER)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "mesh_term": ["Disease", "Depressive Disorder", "Depression", "Depressive Disorder, Major", "Venlafaxine Hydrochloride"], "id": "NCT00090649"}